Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression

The ANALLISA study is a fast, proof-of-concept, phase II clinical trial which aims to assess the efficacy of niraparib rechallenge treatment after secondary cytoreductive surgery in ovarian cancer (OC) patients with oligometastatic progression (OMP) after first maintenance therapy with any PARP inhibitor. A total of 30 patients with OC and OMP will be enrolled and will receive treatment with niraparib 300 or 200 mg, according to body weight or platelet count. Patients will start treatment within 8 weeks after surgery and will receive it until progressive disease or treatment discontinuation. T

Trial Details

NCT ID
NCT06180356
Phase
PHASE2
Sponsor
MedSIR
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Niraparib oral tablets
Locations (sample)
  • A Coruña, Spain|43.37135,-8.396
  • Barakaldo, Spain|43.29639,-2.98813
  • Barcelona, Spain|41.38879,2.15899
  • Girona, Spain|41.98311,2.82493
  • Jaén, Spain|37.76922,-3.79028

Key Eligibility Criteria

  • Written informed consent form (ICF) prior to beginning specific protocol procedures.
  • Female patients ≥ 18 years of age.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  • Patients must have a life expectancy ≥16 weeks.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →